Continuous Glucose Monitoring Following Hospital Discharge
NCT: NCT05360056 · ACTIVE_NOT_RECRUITING
Brief Summary
In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.
Frequently Asked Questions
What is Continuous Glucose Monitoring Following Hospital Discharge?
Continuous Glucose Monitoring Following Hospital Discharge is a clinical trial registered under NCT05360056. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT05360056?
The current status of NCT05360056 (Continuous Glucose Monitoring Following Hospital Discharge) is: ACTIVE_NOT_RECRUITING.
When did Continuous Glucose Monitoring Following Hospital Discharge start?
Continuous Glucose Monitoring Following Hospital Discharge started on 2022-04-26.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.